MRUS News and Press, Merus N.V. From 05/29/24

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg, M.D....

2024-05-28 21:15:01 ET Citigroup analyst issues BUY recommendation for MRUS on May 28, 2024 08:02PM ET. The previous analyst recommendation was Buy. MRUS was trading at $54.87 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

2024-05-28 16:12:04 ET More on Merus Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy) Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement Merus rallies on publication of oncology study abstracts Merus gets FDA breakthr...

2024-05-28 14:00:08 ET Etzer Darout from BMO Capital issued a price target of $84.00 for MRUS on 2024-05-28 11:51:00. The adjusted price target was set to $84.00. At the time of the announcement, MRUS was trading at $53.86. The overall price target consensus is at $61.75...

2024-05-28 12:00:11 ET Bradley Canino from Stifel Nicolaus issued a price target of $90.00 for MRUS on 2024-05-28 10:25:00. The adjusted price target was set to $90.00. At the time of the announcement, MRUS was trading at $54.8. The overall price target consensus is at $...

67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28 th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage onco...

A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 428.5% to $0.983 on volume of 924,758,481 shares Greenwave Technology Solutions Inc. (GWAV) fell 4.2% to $0.0849 on volume of 393,457,542 shares Netcapital Inc. (NCPL) rose 10.1% to $0.1925 on volum...

2024-05-24 13:00:44 ET Summary Merus N.V. is experiencing significant growth and entering a higher price territory, making the risk-reward less clear. The company's bispecific antibody, petosemtamab, showed promising results in a phase 2 study for head and neck squamous cell carci...

2024-05-24 12:58:09 ET More on BioAtla, HOOKIPA Pharma, etc. BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript AEye, Inc. (LIDR) Q1 2024 Earnings Call Transcript BioAtla: A Buried ADC Concern Gets Some New Life In 2024 AEye Q1 2024 Earnings Preview ...